Methyl cinnamate is a sweet balsamic phenylpropanoid ester best known in aroma materials such as strawberry gum, sugandha kokila berry, and smaller fractions of Peru balsam. The strongest public evidence supports its chemical identity, flavor-use safety review, and a growing preclinical literature around inflammatory signaling. Those mechanistic and animal findings are still early-stage, so AromaForge should frame methyl cinnamate as a chemically distinctive aroma constituent with promising but nonclinical bioactivity research rather than as a proven therapeutic agent.
Aroma and practical use
- Use the recorded sweet, balsamic, fruity, cinnamon-like, strawberry-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2023 mouse and cell study reported that methyl cinnamate reduced dextran-sulfate-sodium colitis severity, preserved colon barrier integrity, lowered inflammatory cytokine expression, and was associated with reduced MAPK signaling.
A 2023 mouse and cell study reported that methyl cinnamate reduced dextran-sulfate-sodium colitis severity, preserved colon barrier integrity, lowered inflammatory cytokine expression, and was associated with reduced MAPK signaling.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2018 full-text study comparing cinnamates, acrylates, and methacrylates in RAW264.7 cells reported potent anti-inflammatory activity for methyl cinnamate with less cytotoxicity and less pro-inflammatory behavior than several related compounds.
A 2018 full-text study comparing cinnamates, acrylates, and methacrylates in RAW264.7 cells reported potent anti-inflammatory activity for methyl cinnamate with less cytotoxicity and less pro-inflammatory behavior than several related compounds.
This experimental finding does not establish benefit, dose or safety in people using this blend.
An Ocotea quixos essential-oil study reported that both the whole oil and its main constituents trans-cinnamaldehyde and methyl cinnamate showed anti-inflammatory activity in carrageenan-induced rat paw edema and mouse pleurisy models.
An Ocotea quixos essential-oil study reported that both the whole oil and its main constituents trans-cinnamaldehyde and methyl cinnamate showed anti-inflammatory activity in carrageenan-induced rat paw edema and mouse pleurisy models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedWHO JECFA lists methyl cinnamate as having no safety concern at current levels of intake when used as a flavouring agent.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
That flavor-use conclusion should not be stretched into broad concentrated-use or therapeutic safety claims.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
A dedicated up-to-date dermal-fragrance safety limit was not verified in this pass, although older fragrance safety reviews exist.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
MAPK-pathway downregulation
MAPK-pathway downregulation
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
lower inflammatory mediator output with relatively low RAW264.7 cytotoxicity
lower inflammatory mediator output with relatively low RAW264.7 cytotoxicity
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (4)
- No human clinical trials specific to isolated methyl cinnamate were verified in this pass.
- Most benefit-style data are preclinical and should not be translated into consumer medical claims.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.